An analysis of FDA-approved drugs for cardiovascular diseases.
Drug Discov Today
; 21(1): 1-4, 2016 Jan.
Article
em En
| MEDLINE
| ID: mdl-25218930
ABSTRACT
Following the introduction of antibiotic therapy and widespread inoculations, cardiovascular diseases have leapt ahead of infectious diseases in terms of prevalence in much of the developed and developing world. Herein, we assess FDA-approved drugs for the treatment of cardiovascular diseases. The drug development enterprise around cardiovascular diseases has remained stable in contrast to turbulent changes in other therapeutic indications. However, upon closer inspection, the results identify narrow scope in terms of the breadth of targets and the mechanistic actions of new drugs. From the public health point of view, it is important to balance incremental change with orthogonal innovations that are needed to combat a leading cause of morbidity and mortality.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Fármacos Cardiovasculares
/
Doenças Cardiovasculares
Tipo de estudo:
Risk_factors_studies
Limite:
Humans
País como assunto:
America do norte
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article